

Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management

NICE guideline

Published: 19 March 2024

www.nice.org.uk/guidance/ng240

Your responsibility

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the [Yellow Card Scheme](#).

Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should [assess and reduce the environmental impact of implementing NICE recommendations](#) wherever possible.

Contents

Overview	6
Who is it for?	6
Recommendations.....	7
1.1 Recognising bacterial meningitis and meningococcal disease	7
1.2 Transfer to hospital and antibiotics before arrival at hospital.....	22
1.3 Information and support for people with suspected bacterial meningitis or meningococcal disease	23
1.4 Investigating suspected bacterial meningitis in hospital.....	24
1.5 Investigating suspected meningococcal disease in hospital	30
1.6 Antibiotics for bacterial meningitis in hospital.....	32
1.7 Antibiotics for meningococcal disease in hospital	42
1.8 Corticosteroids for bacterial meningitis and meningococcal disease	43
1.9 Fluid restriction, osmotic agents and intracranial pressure monitoring for confirmed bacterial meningitis.....	44
1.10 Assessing for immunodeficiency and recurrence risk in people with bacterial meningitis or meningococcal disease	46
1.11 Information and support after diagnosis	47
1.12 Preparing for hospital discharge.....	49
1.13 Care after hospital discharge	52
1.14 Recurrent bacterial meningitis and meningococcal disease	55
Terms used in this guideline.....	57
Recommendations for research	60
1 Long-term outcomes of bacterial meningitis.....	60
2 Novel diagnostic techniques applied to blood or cerebrospinal fluid.....	60
3 Duration of antibiotic treatment for meningitis caused by Enterobacterales (coliforms).....	61
4 Intracranial pressure monitoring.....	61
5 Corticosteroids for newborn babies with bacterial meningitis.....	61
Rationale and impact.....	63

Recognising bacterial meningitis and meningococcal disease	63
When to suspect bacterial meningitis	63
When to suspect meningococcal disease	65
Safety netting and alternative causes	66
Transfer to hospital and antibiotics before arrival at hospital	67
Information and support for people with suspected bacterial meningitis or meningococcal disease	68
Timing of investigations and antibiotics for bacterial meningitis	68
Bacterial throat swabs and blood tests for bacterial meningitis	69
Neuroimaging	70
Lumbar puncture	71
Cerebrospinal fluid investigations	72
Investigating suspected meningococcal disease in hospital	73
Antibiotics for bacterial meningitis in hospital	74
Antibiotics for bacterial meningitis in hospital, when the causative organism is known	76
Antibiotic allergy with bacterial meningitis	78
Antibiotics for meningococcal disease in hospital	78
Corticosteroids for bacterial meningitis and meningococcal disease	79
Fluid restriction, osmotic agents and intracranial pressure monitoring for confirmed bacterial meningitis	81
Assessing for immunodeficiency and recurrence risk in people with bacterial meningitis or meningococcal disease	84
Information and support after diagnosis	85
Identifying and managing complications	86
Planning for care after discharge	87
Care after hospital discharge	88
Recurrent bacterial meningitis and meningococcal disease	89
Context	91
Finding more information and committee details	92

Update information 93

This guideline replaces CG102.

This guideline should be read in conjunction with NG195.

Overview

This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.

For recommendations on meningitis in babies up to and including 28 days corrected gestational age, see the [NICE guideline on neonatal infection](#).

This guideline does not cover people with immunodeficiency, confirmed viral, tuberculous or fungal meningitis, confirmed viral encephalitis, brain tumours, hydrocephalus, intracranial shunts, previous neurosurgical procedures, or known cranial or spinal anomalies that increase the risk of bacterial meningitis.

Who is it for?

- Healthcare professionals
- Commissioners and providers
- People with bacterial meningitis or meningococcal disease, their families and carers

Recommendations

People have the right to be involved in discussions and make informed decisions about their care, as described in [NICE's information on making decisions about your care](#).

[Making decisions using NICE guidelines](#) explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.

Recommendations on bacterial meningitis also cover meningococcal meningitis without meningococcal sepsis. Recommendations on meningococcal disease cover meningococcal sepsis with or without meningococcal meningitis.

For recommendations on treating bacterial meningitis in newborn babies in hospital, see the [NICE guideline on neonatal infection](#).

For more guidance on recognising, diagnosing and managing sepsis (including for newborn babies), see the [NICE guideline on suspected sepsis](#).

1.1 Recognising bacterial meningitis and meningococcal disease

1.1.1 When considering a diagnosis of bacterial meningitis or meningococcal disease, be aware that:

- they are rapidly evolving conditions
- they can present with non-specific symptoms and signs (without the [red flag combination for bacterial meningitis in recommendation 1.1.4](#) or any of the [red flag symptoms for meningococcal disease in recommendation 1.1.9](#)), particularly in [young babies](#) and [older adults](#)

- they may be difficult to distinguish from other infections with similar symptoms and signs
- symptoms and signs may be more difficult to identify in [young people](#) and [young adults](#), who may appear well at presentation
- meningitis and sepsis can occur at the same time, particularly in people with a rash.

1.1.2 Complete an assessment of signs, symptoms and risk factors using:

- the [section on when to suspect bacterial meningitis](#), including recommendation 1.1.4 on the red flag combination **and**
- the [section on when to suspect meningococcal disease](#), including recommendation 1.1.9 on the red flag symptoms **and**
- family member and carer reports of symptoms, if relevant.

1.1.3 For people with reduced consciousness or communication difficulties, ask family members or carers about recent changes in symptoms.

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on recognising bacterial meningitis and meningococcal disease](#).

Full details of the evidence and the committee's discussion are in [evidence review A1: symptoms and signs associated with bacterial meningitis](#) and [evidence review A3: symptoms and signs associated with meningococcal disease](#).

When to suspect bacterial meningitis

1.1.4 [Strongly suspect](#) bacterial meningitis in people with all the symptoms in the red flag combination:

- fever
- headache

- neck stiffness
 - altered level of consciousness or cognition (including confusion or delirium).
- 1.1.5 Bacterial meningitis can still be strongly suspected based on clinical assessment, even in people who do not have all the symptoms in the red flag combination.
- 1.1.6 Suspect bacterial meningitis based on assessment of the symptoms and signs in table 1 (for babies, children and young people) or table 2 (for adults), and the [section on risk factors](#). Take into account that:
- bacterial meningitis can present with any of these symptoms and signs
 - the more symptoms and signs a person has, the more likely it is that they have bacterial meningitis.
- 1.1.7 If you suspect or strongly suspect bacterial meningitis, transfer the person to hospital as an emergency (see the [recommendations on transfer to hospital](#)).

Table 1 Symptoms and signs that may indicate bacterial meningitis in babies, children and young people

Symptoms and signs in babies, children and young people	Notes
Red flag combination	–
Fever, headache, neck stiffness, and altered level of consciousness or cognition (including confusion or delirium)	Fever and neck stiffness are less common in babies. Headache and neck stiffness are harder to identify in babies and young children . See recommendations 1.1.4 to 1.1.6 on when to strongly suspect or suspect bacterial meningitis.
Appearance	–
Bulging fontanelle	In babies and young children with an open fontanelle.

Fever	<p>Fever, headache, neck stiffness and altered level of consciousness or cognition are the red flag combination for bacterial meningitis.</p> <p>Fever is less common in babies.</p> <p>Ask the child or young person (or their family members or carers) if they have taken antipyretics, because this may make fever harder to identify.</p> <p>For other possible causes of fever in under 5s, see table 3 in the NICE guideline on fever in under 5s.</p> <p>For children under 6 months, see recommendation 1.2.11 in the NICE guideline on fever in under 5s.</p>
Ill appearance	<p>Ask the child or young person (or their family members or carers) if they have taken antipyretics, because this may make ill appearance harder to identify.</p>
Non-blanching petechial or purpuric rash	<p>Mainly in meningococcal disease (with or without meningococcal meningitis). See table 3 on symptoms and signs that may indicate meningococcal disease.</p> <p>Check all over the body and look for petechiae in the conjunctivae.</p> <p>May be difficult to see on brown, black or tanned skin.</p>
Pale, mottled skin or cyanosis	<p>May be difficult to see on brown, black or tanned skin.</p>
Behaviour	–
Irritability	Common in babies and young children.
Lethargy	Common in babies and young children.
Reduced feeding	In babies.

Unusual behaviour	<p>For example, the person may be agitated, aggressive or subdued.</p> <p>Ask family members or carers about changes in the child or young person's behaviour.</p> <p>For more guidance on identifying changes in babies, children and young people who do not communicate verbally, see recommendation 1.2.14 in the NICE guideline on babies, children and young people's experience of care.</p>
Weak, high-pitched or continuous cry	In babies.
Cardiovascular	–
Early signs of sepsis Signs of shock	<p>See table 3 on symptoms and signs that may indicate meningococcal disease.</p> <p>For more guidance on assessing for sepsis, see the sections on evaluating risk in the NICE guideline on suspected sepsis.</p>
Neurological	–
Altered level of consciousness or altered cognition (including confusion or delirium)	Fever, headache, neck stiffness and altered level of consciousness or cognition are the red flag combination for bacterial meningitis.
Focal neurological deficits	–
Headache	<p>Fever, headache, neck stiffness and altered level of consciousness or cognition are the red flag combination for bacterial meningitis.</p> <p>Babies and children and young people with cognitive impairment or communication difficulties may not be able to report headache.</p>

Neck stiffness, including more subtle discomfort or reluctance to move the neck	<p>Fever, headache, neck stiffness and altered level of consciousness or cognition are the red flag combination for bacterial meningitis.</p> <p>Neck stiffness is less likely and harder to identify in babies.</p> <p>Neck stiffness is harder to identify in children and young people with cognitive impairment or communication difficulties.</p>
Photophobia	Harder to identify in babies.
Seizures	–
Respiratory	–
Tachypnoea, apnoea, and grunting	Non-specific signs of illness, including sepsis and meningitis in babies.
Other	–
Unexplained body pain, including limb, back or abdominal pain	–
Vomiting	–

Table 2 Symptoms and signs that may indicate bacterial meningitis in adults

Symptoms and signs in adults	Notes
Red flag combination	–
Fever, headache, neck stiffness, and altered level of consciousness or cognition (including confusion or delirium)	<p>Fever is less common in <u>older adults</u>.</p> <p>Headache and neck stiffness are harder to identify in adults with cognitive impairment.</p> <p>Neck stiffness is harder to identify in adults with dementia or arthritis.</p> <p>Altered level of consciousness or cognition may be missed in <u>young adults</u> and older adults.</p> <p>See recommendations 1.1.4 to 1.1.6 on when to strongly suspect or suspect bacterial meningitis.</p>

Symptoms and signs in adults	Notes
Appearance	–
Fever	<p>Fever, headache, neck stiffness and altered level of consciousness or cognition are the red flag combination for bacterial meningitis.</p> <p>Ask the person (or their family members or carers) if they have taken antipyretics, because this may make fever harder to identify.</p> <p>Fever is less common in older adults.</p>
Ill appearance	Ask the person (or their family members or carers) if they have taken antipyretics, because this may make ill appearance harder to identify.
Non-blanching petechial or purpuric rash	<p>Mainly in meningococcal meningitis and meningococcal disease (with or without meningococcal meningitis). See table 3 on symptoms and signs that may indicate meningococcal disease.</p> <p>Check all over the body and look for petechiae in the conjunctivae.</p> <p>May be difficult to see on brown, black or tanned skin.</p>
Pale, mottled skin or cyanosis	May be difficult to see on brown, black or tanned skin.
Behaviour	–
Irritability	–
Lethargy	Common in older adults.
Unusual behaviour	<p>For example, the person may be agitated, aggressive or subdued.</p> <p>Bacterial meningitis may be missed in older adults with delirium or altered consciousness.</p> <p>In young people and young adults, altered behaviour may be incorrectly assumed to be caused by alcohol or substance misuse, and bacterial meningitis can be missed as a result.</p>
Cardiovascular	–

Symptoms and signs in adults	Notes
Early signs of sepsis Signs of shock	See table 3 on symptoms and signs that may indicate meningococcal disease . For more guidance on assessing for sepsis, see the sections on evaluating risk in the NICE guideline on suspected sepsis .
Neurological	–
Altered level of consciousness or altered cognition (including confusion or delirium)	Fever, headache, neck stiffness and altered level of consciousness or cognition are the red flag combination for bacterial meningitis. Bacterial meningitis may be missed in older adults with delirium or altered consciousness. In young people and young adults, altered level of consciousness may be incorrectly assumed to be caused by alcohol or substance misuse, and bacterial meningitis can be missed as a result.
Focal neurological deficits	–
Headache	Fever, headache, neck stiffness and altered level of consciousness or cognition are the red flag combination for bacterial meningitis. Adults with cognitive impairment or communication difficulties may not be able to report headache.
Neck stiffness, including more subtle discomfort or reluctance to move the neck	Fever, headache, neck stiffness and altered level of consciousness or cognition are the red flag combination for bacterial meningitis. Neck stiffness is less likely and harder to identify in older adults. Neck stiffness is harder to identify in adults with cognitive impairment, communication difficulties, dementia or arthritis.
Photophobia	–
Seizures	–

Symptoms and signs in adults	Notes
Other	–
Unexplained body pain, including limb, back or abdominal pain	–
Vomiting	–

Risk factors

1.1.8 Be on heightened alert to the possibility of bacterial meningitis (including meningococcal meningitis) in people with any of these risk factors:

- missed relevant immunisations, such as meningococcal, Haemophilus influenzae type b (Hib) or pneumococcal vaccines
- reduced or absent spleen function
- congenital complement deficiency or acquired inhibition
- they are a student in further or higher education, particularly if they are in large shared accommodation (such as halls of residence)
- a family history of meningococcal disease
- they have been in contact with someone with Hib disease or meningococcal disease, or have been in an area with an outbreak of meningococcal disease
- a previous episode of bacterial meningitis or meningococcal disease
- a cerebrospinal fluid leak
- a cochlear implant.

For newborn babies, see the risk factors for neonatal infection (not specific to meningitis) in the NICE guideline on neonatal infection:

- [risk factors for and clinical indicators of possible early-onset neonatal infection](#)
- [risk factors for and clinical indicators of possible late-onset neonatal infection](#).

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on when to suspect bacterial meningitis](#).

Full details of the evidence and the committee's discussion are in [evidence review A1: symptoms and signs associated with bacterial meningitis](#) and [evidence review A2: risk factors associated with bacterial meningitis](#).

When to suspect meningococcal disease

- 1.1.9 [Strongly suspect](#) meningococcal disease in people with any of these red flag symptoms:
- haemorrhagic, non-blanching rash with lesions larger than 2 mm (purpura)
 - rapidly progressive and/or spreading non-blanching petechial or purpuric rash
 - any symptoms and signs of bacterial meningitis (see [tables 1 and 2](#)), when combined with a non-blanching petechial or purpuric rash.
- 1.1.10 Do not rule out meningococcal disease just because a person does not have a rash.
- 1.1.11 Suspect meningococcal disease based on assessment of the symptoms and signs in table 3, and the [section on risk factors](#). Take into account that meningococcal disease can present with any combination of the non-specific symptoms and signs of severe illness in table 3.
- 1.1.12 When looking for a rash:
- check all over the body (including nappy areas), and check for petechiae in the conjunctivae
 - note that rashes can be hard to detect on brown, black or tanned skin (look for petechiae in the conjunctiva)
 - tell the person and their family members or carers to look out for any

changes in the rash, because it can change from blanching to non-blanching.

1.1.13 If you suspect or strongly suspect meningococcal disease, transfer the person to hospital as an emergency (see the [recommendations on transfer to hospital](#)).

Table 3 Symptoms and signs that may indicate meningococcal disease for babies, children, young people and adults

Symptom or sign	Notes
Red flags	–
Haemorrhagic, non-blanching rash with lesions larger than 2 mm (purpura) Rapidly progressive and/or spreading non-blanching petechial or purpuric rash Any symptoms and signs of bacterial meningitis (see tables 1 and 2), when combined with a non-blanching petechial or purpuric rash	Check all over the body and look for petechiae in the conjunctivae. Rashes may be difficult to see on brown, black or tanned skin.
Non-specific symptom or sign	–
Appearance	–
Ill appearance	Ask the person (or their family members or carers) if they have taken antipyretics, because this may make ill appearance harder to identify.
Pale, mottled skin or cyanosis	May be difficult to see on brown, black or tanned skin.
Parent or carer concern	–
Behaviour	–
Lethargy, does not wake or if roused does not stay awake	Common in babies, young children and older adults.

Unusual behaviour	<p>For example, the person may be agitated, aggressive or subdued.</p> <p>Meningococcal disease may be missed in older adults with delirium or altered consciousness.</p> <p>In young people and young adults, altered behaviour may be incorrectly assumed to be caused by alcohol or substance misuse, and meningococcal disease can be missed as a result.</p>
Weak, high-pitched or continuous cry	In babies.
Cardiovascular	–
Cold hands and feet	–
Heart rate less than 60 beats per minute	In babies and children under 12 years.
High age-specific heart rate	For age-specific heart rates, see the sections on evaluating risk in the NICE guideline on suspected sepsis .
Low age-specific blood pressure	For age-specific blood pressures, see the sections on evaluating risk in the NICE guideline on suspected sepsis .
Hydration	–
Capillary refill time of 3 seconds or longer	–
Reduced urine output	–
Neurological	–
Altered level of consciousness or altered cognition (including confusion or delirium)	<p>Meningococcal disease may be missed in older adults with delirium or altered consciousness.</p> <p>In young people and young adults, altered level of consciousness may be incorrectly assumed to be caused by alcohol or substance misuse, and meningococcal disease can be missed as a result.</p>
Respiratory	–

Grunting	In babies and children.
High age-specific respiratory rate	For age-specific respiratory rates, see the sections on evaluating risk in the NICE guideline on suspected sepsis .
Temperature	–
Fever	<p>Ask the person (or their family members or carers) if they have taken antipyretics, because this may make fever harder to identify.</p> <p>Fever is a particular concern for babies at the levels specified in the NICE guideline on suspected sepsis:</p> <ul style="list-style-type: none"> • 39°C or higher in children aged 3 to 6 months • 38°C or higher in children younger than 3 months.
Temperature less than 36°C	–
Other	–
Abdominal pain	–
Diarrhoea	–
Leg pain	–

Risk factors

1.1.14 Be on heightened alert to the possibility of meningococcal disease in people with any of these risk factors:

- missed meningococcal vaccinations
- reduced or absent spleen function
- complement deficiency or inhibition
- they are a student in further or higher education, particularly if they are in

large shared accommodation (such as halls of residence)

- a family history of meningococcal disease
- they have been in contact with someone with meningococcal disease, or have been in an area with an outbreak
- a previous episode of meningococcal disease.

1.1.15 For people who have had a previous episode of meningococcal disease, also check for [risk factors for recurrent bacterial meningitis and meningococcal disease](#).

For newborn babies, see the risk factors for neonatal infection (not specific to meningococcal disease) in the NICE guideline on neonatal infection:

- [risk factors for and clinical indicators of possible early-onset neonatal infection](#)
- [risk factors for and clinical indicators of possible late-onset neonatal infection](#).

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on when to suspect meningococcal disease](#).

Full details of the evidence and the committee's discussion are in [evidence review A3: symptoms and signs associated with meningococcal disease](#) and [evidence review A4: risk factors associated with meningococcal disease](#).

Safety netting

1.1.16 If you send a person home after clinical assessment for bacterial meningitis and meningococcal disease:

- give safety netting advice (see [recommendation 1.3.2](#))
- ask them to return for further assessment if they develop new symptoms, if a rash changes from blanching to non-blanching, or if existing symptoms get

worse.

Alternative causes

- 1.1.17 Be aware that many of the symptoms and signs of bacterial meningitis and meningococcal disease are also indicators of many other serious conditions in babies, children, young people and adults (for example, other forms of sepsis, non-bacterial meningitis, intracranial bleed or ischaemia, and pneumonia).

For guidance on assessing for sepsis, see the [NICE guideline on suspected sepsis](#).

For guidance on assessing fever in children under 5, see the [section on clinical assessment of children with fever in the NICE guideline on fever in under 5s](#).

For guidance on diagnosing and managing stroke and transient ischaemic attack in over 16s, see the [NICE guideline on stroke](#).

For guidance on diagnosing and managing pneumonia in adults, see the [NICE guideline on pneumonia](#).

For guidance on initial assessment and management of suspected acute respiratory infection in over 16s, see the [NICE guideline on acute respiratory infection](#).

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on safety netting and alternative causes](#).

Full details of the evidence and the committee's discussion are in [evidence review A1: symptoms and signs associated with bacterial meningitis](#) and [evidence review A3: symptoms and signs associated with meningococcal disease](#).

1.2 Transfer to hospital and antibiotics before arrival at hospital

- 1.2.1 Transfer people with suspected bacterial meningitis or meningococcal disease to hospital as an emergency.
- 1.2.2 Tell the hospital that a person with suspected bacterial meningitis or meningococcal disease is being transferred and that they will need assessment by a senior clinical decision maker.
- 1.2.3 Do not delay transfer to hospital to give antibiotics to people with suspected or strongly suspected bacterial meningitis or meningococcal disease.
- 1.2.4 If there is likely to be a clinically significant delay in transfer to hospital for people with strongly suspected bacterial meningitis, give intravenous or intramuscular ceftriaxone or benzylpenicillin outside of hospital.
- 1.2.5 For people with strongly suspected meningococcal disease, give intravenous or intramuscular ceftriaxone or benzylpenicillin as soon as possible outside of hospital, unless this will delay transfer to hospital.
- 1.2.6 Do not give antibiotics outside of hospital if the person has severe antibiotic allergy to either ceftriaxone or benzylpenicillin.

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on transfer to hospital and antibiotics before arrival at hospital](#).

Full details of the evidence and the committee's discussion are in:

- [evidence review A1: symptoms and signs associated with bacterial meningitis](#)
- [evidence review A3: symptoms and signs of associated with meningococcal disease](#)
- [evidence review C1: timing of antibiotics for bacterial meningitis](#)
- [evidence review C2: timing of antibiotics for meningococcal disease](#).

1.3 Information and support for people with suspected bacterial meningitis or meningococcal disease

1.3.1 Discuss the following with people who are in hospital with suspected bacterial meningitis or meningococcal disease and their family members and carers:

- the reasons for their suspected diagnosis, and any uncertainty about this
- when they can expect to know more
- the need for investigations (including lumbar puncture for bacterial meningitis)
- the timing of investigations and antibiotics.

1.3.2 For people who are unlikely to have bacterial meningitis or meningococcal disease, but who are sent home from hospital with an unconfirmed diagnosis:

- explain which symptoms and signs to look out for, and what changes should prompt them to return to hospital

- direct them to sources of online information.

For more guidance on providing information to adults, see the NICE guideline on patient experience in adult NHS services. In particular, see the sections on:

- [knowing the patient as an individual](#)
- [communication](#)
- [information](#).

For more guidance on providing information to babies, children and young people, see the NICE guideline on babies, children and young people's experience of healthcare. In particular, see the sections on:

- [communication by healthcare staff](#)
- [providing information](#).

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on information and support for people with suspected bacterial meningitis or meningococcal disease](#).

Full details of the evidence and the committee's discussion are in [evidence review K1: information for suspected bacterial meningitis or meningococcal disease](#) and [evidence review K2: support for suspected bacterial meningitis or meningococcal disease](#).

1.4 Investigating suspected bacterial meningitis in hospital

Timing of investigations and antibiotics

- 1.4.1 A [senior clinical decision maker](#) should perform an initial assessment and ensure that:

- antibiotics start within 1 hour of the person with suspected bacterial meningitis arriving at hospital, and in line with the [section on antibiotics for bacterial meningitis in hospital](#)
- blood tests and lumbar puncture are performed before starting antibiotics (if it is safe to do so and will not cause a clinically significant delay to starting antibiotics), and in line with the [sections on blood tests](#) and [lumbar puncture](#).

For a short explanation of why the committee made this recommendation and how it might affect practice, see the [rationale and impact section on timing of investigations and antibiotics for bacterial meningitis](#).

Full details of the evidence and the committee's discussion are in [evidence review B1: investigating and diagnosing suspected bacterial meningitis with blood and urine investigations](#) and [evidence review C1: timing of antibiotics for bacterial meningitis](#).

Making a diagnosis

1.4.2 Confirm a diagnosis of bacterial meningitis based on:

- clinical features **and**
- blood test results **and**
- lumbar puncture results.

For a short explanation of why the committee made this recommendation and how it might affect practice, see the [rationale and impact section on lumbar puncture](#).

Full details of the evidence and the committee's discussion are in [evidence review B3: investigating and diagnosing suspected bacterial meningitis with cerebrospinal fluid parameters](#) and [evidence review C1: timing of antibiotics for bacterial meningitis](#).

Bacterial throat swab

- 1.4.3 For people with suspected bacterial meningitis, perform a bacterial throat swab for meningococcal culture, preferably before starting antibiotics. Indicate on the request form that this is specifically for meningococcal culture.

Blood tests

- 1.4.4 Perform the following blood tests for people with suspected bacterial meningitis:
- blood culture
 - white blood cell count (including neutrophils)
 - blood C-reactive protein (CRP), or procalcitonin (PCT) if CRP is not available
 - blood glucose
 - whole-blood diagnostic polymerase chain reaction (PCR), including meningococcal and pneumococcal
 - HIV test (in line with [recommendations 1.10.1 and 1.10.2](#)).
- 1.4.5 Do not rule out bacterial meningitis based only on a normal CRP, PCT, or white blood cell count.

For guidance on blood tests for sepsis, see the sections on managing suspected sepsis in the [NICE guideline on suspected sepsis](#).

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on bacterial throat swabs and blood tests for bacterial meningitis](#).

Full details of the evidence and the committee's discussion are in [evidence review B1: investigating and diagnosing suspected bacterial meningitis with blood and urine investigations](#) and [evidence review C1: timing of antibiotics for bacterial meningitis](#).

Neuroimaging

1.4.6 Do not routinely perform neuroimaging before lumbar puncture.

1.4.7 Perform imaging if the person has:

- risk factors for an evolving space-occupying lesion **or**
- any of these symptoms or signs, which might indicate raised intracranial pressure:
 - new focal neurological features (including seizures or posturing)
 - abnormal pupillary reactions
 - a Glasgow Coma Scale (GCS) score of 9 or less, or a progressive and sustained or rapid fall in level of consciousness.

Do not perform a lumbar puncture until these factors have been resolved.

1.4.8 Take bloods, give antibiotics and stabilise the person before imaging.

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on neuroimaging](#).

Full details of the evidence and the committee's discussion are in [evidence review B4: factors associated with brain herniation](#) and [evidence review B5: role of neuroimaging prior to lumbar puncture](#).

Lumbar puncture

1.4.9 Perform the lumbar puncture before starting antibiotics, unless it is not safe to do so or it will cause a clinically significant delay to starting antibiotics.

1.4.10 If the person has started on antibiotics before having a lumbar puncture, perform a lumbar puncture as soon as possible (if it is safe to perform).

1.4.11 Treat and stabilise any of the following before performing a lumbar puncture:

- unprotected airway
- respiratory compromise
- shock
- uncontrolled seizures
- bleeding risk.

1.4.12 Do not perform lumbar puncture if there is:

- extensive or rapidly spreading purpura
- infection at the lumbar puncture site
- risk factors for an evolving space-occupying lesion (follow [recommendation 1.4.7 on imaging](#))
- any of these symptoms or signs, which might indicate raised intracranial pressure (follow recommendation 1.4.7 on imaging):
 - new focal neurological features (including seizures or posturing)
 - abnormal pupillary reactions
 - a Glasgow Coma Scale (GCS) score of 9 or less, or a progressive and sustained or rapid fall in level of consciousness.

1.4.13 Measure blood glucose in people immediately before lumbar puncture, so that the cerebrospinal fluid to blood glucose ratio can be calculated.

For information about investigations and when to perform a lumbar puncture in newborn babies with suspected meningitis, see the NICE guideline on neonatal infection:

- [investigations before starting antibiotics in babies who may have early-onset infection](#)
- [investigations during antibiotic treatment for early-onset neonatal infection](#)
- [investigations before starting antibiotics in babies who may have late-onset infection](#)

- [investigations during antibiotic treatment for late-onset neonatal infection](#).

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on lumbar puncture](#).

Full details of the evidence and the committee's discussion are in [evidence review B3: investigating and diagnosing suspected bacterial meningitis with cerebrospinal fluid parameters](#) and [evidence review C1: timing of antibiotics for bacterial meningitis](#).

Cerebrospinal fluid investigations

- 1.4.14 Perform the following cerebrospinal fluid investigations in people with suspected bacterial meningitis:
- red and white cell count and cell type (including differential white cell count)
 - total protein
 - glucose concentration (to calculate cerebrospinal fluid to blood glucose ratio)
 - microscopy for bacteria (using gram stain)
 - microbiological culture and sensitivities
 - PCR for relevant pathogens.
- 1.4.15 Store the remaining cerebrospinal fluid in case more tests are needed.
- 1.4.16 Ensure that cerebrospinal fluid, cell counts, total protein and glucose concentrations are available within 4 hours of lumbar puncture.
- 1.4.17 When interpreting the results of cerebrospinal fluid investigations, take into account:
- red cells in the sample, which may suggest blood contamination or a different diagnosis
 - whether earlier antibiotics may have reduced the diagnostic reliability of

these investigations

- that the normal thresholds for white cell count and protein may be higher in babies under 3 months.

1.4.18 Interpret cerebrospinal fluid results using standard age-appropriate threshold values (taking into account factors such as earlier antibiotic use or suspected immunodeficiency).

1.4.19 If cerebrospinal fluid results are abnormal, consider alternative viral, mycobacterial, fungal or non-infectious causes as well as bacterial meningitis.

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on cerebrospinal fluid investigations](#).

Full details of the evidence and the committee's discussion are in [evidence review B3: investigating and diagnosing suspected bacterial meningitis with cerebrospinal fluid parameters](#).

1.5 Investigating suspected meningococcal disease in hospital

Timing of investigations and antibiotics

1.5.1 A [senior clinical decision maker](#) should perform an initial assessment and ensure that:

- antibiotics start within 1 hour of the person with suspected meningococcal disease arriving at hospital, and in line with the [section on antibiotics for meningococcal disease in hospital](#).
- blood tests are performed before starting antibiotics, and in line with the [section on blood tests](#).

Bacterial throat swab

- 1.5.2 For people with suspected meningococcal disease, perform a bacterial throat swab for meningococcal culture, preferably before starting antibiotics. Indicate on the request form that this is specifically for meningococcal culture.

Blood tests

- 1.5.3 Perform the following blood tests for people with suspected meningococcal disease:
- blood culture
 - white blood cell count (including neutrophils)
 - blood C-reactive protein (CRP), or procalcitonin (PCT) if CRP is not available
 - lactate
 - whole-blood diagnostic polymerase chain reaction (PCR), including meningococcal and pneumococcal.
- 1.5.4 Do not rule out meningococcal disease based only on a normal CRP, PCT or white blood cell count.

Making a diagnosis

- 1.5.5 Confirm a diagnosis of meningococcal disease based on the blood test results and clinical features.

For guidance on blood tests for sepsis, see the sections on managing suspected sepsis in the [NICE guideline on suspected sepsis](#).

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on investigating suspected meningococcal disease in hospital](#).

Full details of the evidence and the committee's discussion are in [evidence review B2: investigating and diagnosing suspected meningococcal disease with blood and urine investigations](#) and [evidence review C2: timing of antibiotics for meningococcal disease](#).

1.6 Antibiotics for bacterial meningitis in hospital

March 2024: when using ceftriaxone, follow the [Medicines and Healthcare products Regulatory Agency \(MHRA\) safety advice that ceftriaxone is incompatible with solutions containing calcium](#).

- 1.6.1 Take blood samples before giving antibiotics (see the [section on blood tests](#)).
- 1.6.2 If it is safe to do so and will not cause a clinically significant delay to starting antibiotics, perform a lumbar puncture before giving antibiotics (see the [sections on lumbar puncture](#) and [cerebrospinal fluid investigations](#)).
- 1.6.3 Give intravenous antibiotics as soon as bacterial meningitis is suspected, within 1 hour of arrival in hospital (after taking blood samples and performing a lumbar puncture).
- 1.6.4 Get [infection specialist](#) advice for all cases of bacterial meningitis. This is particularly important for:
 - people who have recently travelled outside of the UK and may be at risk of antimicrobial resistance
 - people who are colonised with cephalosporin-resistant [Enterobacterales \(coliforms\)](#).

See the [recommendation on antibiotic allergy for alternative antibiotics for each causative organism](#).

For guidance on antibiotics for newborn babies, see:

- the [section on early- and late-onset meningitis in the NICE guideline on neonatal infection](#)
- [recommendation 1.14.6 in the NICE guideline on suspected sepsis](#).

For guidance on antimicrobial stewardship, see the [NICE guideline on antimicrobial stewardship](#).

Before the causative organism is known, or when it cannot be identified

- 1.6.5 For suspected bacterial meningitis when the causative organism has not been identified:
- give ceftriaxone (use the [highest doses recommended by the BNF or BNFC](#) or refer to local antimicrobial guidance)
 - if ceftriaxone is contraindicated, consider cefotaxime (see the BNFC for contraindications to ceftriaxone for pre-term babies under 41 weeks corrected gestational age).
- 1.6.6 Give intravenous amoxicillin in addition to ceftriaxone or cefotaxime for people with risk factors for *Listeria monocytogenes*.
- 1.6.7 Do not routinely give intravenous aciclovir unless herpes simplex encephalitis is strongly suspected.
- 1.6.8 Continue initial antibiotic treatment until the results of blood and cerebrospinal fluid tests suggest an alternative treatment is needed or there is an alternative diagnosis. If test results are normal, but bacterial meningitis is still suspected, get advice from an [infection specialist](#).
- 1.6.9 If the cerebrospinal fluid results suggest bacterial meningitis, but the blood culture and whole-blood diagnostic polymerase chain reaction are negative:

- continue antibiotics for 10 days
- after 10 days, stop antibiotics if the person has recovered, or get advice from an infection specialist if they have not.

See the [recommendation on antibiotic allergy for alternative antibiotics](#).

For guidance on public health management of meningococcal disease, see the [Public Health England guidance on meningococcal disease](#).

For guidance on antivirals for suspected herpes simplex encephalitis in children under 5, see [recommendation 1.5.20 in the NICE guideline on fever in under 5s](#).

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on antibiotics for bacterial meningitis in hospital](#).

Full details of the evidence and the committee's discussion are in the following evidence reviews:

- [evidence review C1: timing of antibiotics for bacterial meningitis](#)
- [evidence review D1: antibiotics for bacterial meningitis before or in the absence of identifying causative infecting organism in younger infants](#)
- [evidence review D2: antibiotics for bacterial meningitis before or in the absence of identifying causative infecting organism in older infants and children](#)
- [evidence review D3: antibiotics for bacterial meningitis before or in the absence of identifying causative infecting organism in adults](#)
- [evidence review E1: antibiotics for bacterial meningitis caused by *Streptococcus pneumoniae*](#)
- [evidence review E2: antibiotics for bacterial meningitis caused by *Haemophilus influenzae*](#)
- [evidence review E3: antibiotics for bacterial meningitis caused by group B streptococcus](#)
- [evidence review E4: antibiotics for bacterial meningitis caused by gram-negative bacilli](#)
- [evidence review E6: antibiotics for bacterial meningitis caused by *Neisseria meningitidis*](#).

When the causative organism is known

See the [recommendation on antibiotic allergy for alternative antibiotics for each causative organism](#).

Streptococcus pneumoniae

1.6.10 For Streptococcus pneumoniae meningitis:

- give ceftriaxone (use the [highest doses recommended by the BNF](#) or [BNFC](#) or refer to local antimicrobial guidance)
- if ceftriaxone is contraindicated, consider cefotaxime (see the BNFC for contraindications to ceftriaxone for pre-term babies under 41 weeks corrected gestational age)
- after 10 days, stop antibiotics if the person has recovered, or get advice from an [infection specialist](#) if they have not.

Haemophilus influenzae type b

1.6.11 For Haemophilus influenzae type b meningitis:

- give ceftriaxone (use the [highest doses recommended by the BNF](#) or [BNFC](#) or refer to local antimicrobial guidance)
- if ceftriaxone is contraindicated, consider cefotaxime (see the BNFC for contraindications to ceftriaxone for pre-term babies under 41 weeks corrected gestational age)
- get advice from an infection specialist when starting treatment
- after 7 days, stop antibiotics if the person has recovered, or continue for a total of 10 days if they have not
- get further advice from an infection specialist if the person has not recovered after 10 days.

Group B streptococcal meningitis

1.6.12 For group B streptococcal meningitis:

- give ceftriaxone (use the [highest doses recommended by the BNF](#) or [BNFC](#)

or refer to local antimicrobial guidance)

- if ceftriaxone is contraindicated, consider cefotaxime (see the BNFC for contraindications to ceftriaxone for pre-term babies under 41 weeks corrected gestational age)
- get advice from an infection specialist when starting treatment
- after 14 days, stop antibiotics if the person has recovered, or get further advice from an infection specialist if they have not.

Enterobacterales (coliforms)

1.6.13 For meningitis caused by Enterobacterales (coliforms):

- give ceftriaxone (use the highest doses recommended by the BNF or BNFC or refer to local antimicrobial guidance)
- if ceftriaxone is contraindicated, consider cefotaxime (see the BNFC for contraindications to ceftriaxone for pre-term babies under 41 weeks corrected gestational age)
- get advice from an infection specialist on using meropenem as an alternative to ceftriaxone and cefotaxime, while awaiting antibiotic sensitivities
- review treatment once antibiotic sensitivities are available
- after 21 days, stop antibiotics if the person has recovered, or get further advice from an infection specialist if they have not.

Listeria monocytogenes

1.6.14 For meningitis caused by Listeria monocytogenes:

- give intravenous amoxicillin or ampicillin for 21 days
- get advice from an infection specialist on adding intravenous co-trimoxazole for the first 7 days

- after 21 days, stop antibiotics if the person has recovered, or get advice from an infection specialist if they have not.

In March 2024, this was an off-label use of co-trimoxazole. See [NICE's information on prescribing medicines](#).

Neisseria meningitidis

1.6.15 For Neisseria meningitidis:

- give ceftriaxone (use the [highest doses recommended by the BNF](#) or [BNFC](#) or refer to local antimicrobial guidance)
- if ceftriaxone is contraindicated, consider cefotaxime (see the BNFC for contraindications to ceftriaxone for pre-term babies under 41 weeks corrected gestational age)
- after 5 days, stop antibiotics if the person has recovered, or get advice from an infection specialist if they have not.

Tuberculous meningitis

For guidance on risk factors, identification and treatment for tuberculous meningitis, see the [NICE guideline on tuberculosis](#).

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on antibiotics for bacterial meningitis in hospital when the causative organism is known](#).

Full details of the evidence and the committee's discussion are in the following evidence reviews:

- [evidence review D1: antibiotics for bacterial meningitis before or in the absence of identifying causative infecting organism in younger infants](#)
- [evidence review D2: antibiotics for bacterial meningitis before or in the absence of identifying causative infecting organism in older infants and children](#)
- [evidence review D3: antibiotics for bacterial meningitis before or in the absence of identifying causative infecting organism in adults](#)
- [evidence review E1: antibiotics for bacterial meningitis caused by *Streptococcus pneumoniae*](#)
- [evidence review E2: antibiotics for bacterial meningitis caused by *Haemophilus influenzae*](#)
- [evidence review E3: antibiotics for bacterial meningitis caused by group B streptococcus](#)
- [evidence review E4: antibiotics for bacterial meningitis caused by gram-negative bacilli](#)
- [evidence review E5: antibiotics for bacterial meningitis caused by *Listeria monocytogenes*](#)
- [evidence review E6: antibiotics for bacterial meningitis caused by *Neisseria meningitidis*](#).

Antibiotic allergy with bacterial meningitis

1.6.16 In people with an antibiotic allergy:

- ask about the reaction they get
- get advice from an [infection specialist](#), in particular for people who are pregnant
- if their reaction was not [severe allergy](#), consider:
 - ceftriaxone or cefotaxime for suspected meningitis or confirmed meningitis caused by *Streptococcus pneumoniae*, *Haemophilus influenzae* type b, group B streptococcus, Enterobacterales (coliforms), or *Neisseria meningitidis*
 - co-trimoxazole, and either ceftriaxone or cefotaxime for people with risk factors for suspected *Listeria monocytogenes*
- if their reaction was severe allergy, consider:
 - co-trimoxazole or chloramphenicol for people with risk factors for *Listeria monocytogenes*
 - chloramphenicol for suspected meningitis, or confirmed meningitis caused by other causative organisms.

In March 2024, this was an off-label use of co-trimoxazole. See [NICE's information on prescribing medicines](#).

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on antibiotic allergy](#).

Full details of the evidence and the committee's discussion are in the following evidence reviews:

- [evidence review D1: antibiotics for bacterial meningitis before or in the absence of identifying causative infecting organism in younger infants](#)
- [evidence review D2: antibiotics for bacterial meningitis before or in the absence of identifying causative infecting organism in older infants and children](#)
- [evidence review D3: antibiotics for bacterial meningitis before or in the absence of identifying causative infecting organism in adults](#)
- [evidence review E1: antibiotics for bacterial meningitis caused by *Streptococcus pneumoniae*](#)
- [evidence review E2: antibiotics for bacterial meningitis caused by *Haemophilus influenzae*](#)
- [evidence review E3: antibiotics for bacterial meningitis caused by group B streptococcus](#)
- [evidence review E4: antibiotics for bacterial meningitis caused by gram-negative bacilli](#)
- [evidence review E5: antibiotics for bacterial meningitis caused by *Listeria monocytogenes*](#)
- [evidence review E6: antibiotics for bacterial meningitis caused by *Neisseria meningitidis*](#).

1.7 Antibiotics for meningococcal disease in hospital

March 2024: when using ceftriaxone, follow the [Medicines and Healthcare products Regulatory Agency \(MHRA\) safety advice that ceftriaxone is incompatible with solutions containing calcium](#).

- 1.7.1 Give intravenous ceftriaxone for suspected or confirmed meningococcal disease in hospital.
- 1.7.2 After 5 days, stop antibiotics if the person has recovered, or get advice from an [infection specialist](#) if they have not.
- 1.7.3 In people with an antibiotic allergy:
- ask about the reaction they get
 - give ceftriaxone if their reaction was not [severe allergy](#)
 - if their reaction was severe allergy, get advice from an infection specialist and consider chloramphenicol.

For guidance on antibiotics for newborn babies, see:

- the [section on early- and late-onset meningitis in the NICE guideline on neonatal infection](#)
- [recommendation 1.14.6 in the NICE guideline on suspected sepsis](#).

For guidance on antimicrobial stewardship, see the [NICE guideline on antimicrobial stewardship](#).

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on antibiotics for meningococcal disease in hospital settings](#).

Full details of the evidence and the committee's discussion are in [evidence review F: antibiotics for meningococcal disease](#).

1.8 Corticosteroids for bacterial meningitis and meningococcal disease

Bacterial meningitis

In March 2024, all uses of dexamethasone in this section were off-label. See [NICE's information on prescribing medicines](#).

- 1.8.1 For people over 3 months with [strongly suspected](#) or confirmed bacterial meningitis, give intravenous dexamethasone.
- 1.8.2 For babies between 28 days and 3 months old with [strongly suspected](#) or confirmed bacterial meningitis, get [infection specialist](#) advice on using dexamethasone.
- 1.8.3 When the causative organism is found:
 - continue dexamethasone if it is pneumococcus or Haemophilus influenzae type b
 - stop dexamethasone for all other organisms.
- 1.8.4 If no causative organism is found, get advice from an [infection specialist](#) on whether or not to continue dexamethasone.
- 1.8.5 For people receiving dexamethasone:

- give the first dose with or before the first dose of antibiotics if possible
- however, do not delay antibiotics to wait for dexamethasone to be started
- if dexamethasone is delayed for less than 12 hours after the start of antibiotics, give dexamethasone as soon as possible
- if dexamethasone is delayed for more than 12 hours after the start of antibiotics, get advice from an infection specialist and decide whether dexamethasone is still likely to provide benefit.

Meningococcal disease

- 1.8.6 Do not routinely give corticosteroids to people with meningococcal disease.
- 1.8.7 Consider low-dose replacement corticosteroids for people with meningococcal septic shock that is not responding to high-dose vasoactive agents.

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on corticosteroids](#).

Full details of the evidence and the committee's discussion are in [evidence review G4: corticosteroids for treatment of bacterial meningitis](#) and [evidence review H: corticosteroids in meningococcal disease](#).

1.9 Fluid restriction, osmotic agents and intracranial pressure monitoring for confirmed bacterial meningitis

Fluid restriction

- 1.9.1 Do not routinely restrict fluid intake to below routine maintenance needs in people with bacterial meningitis.

1.9.2 Give maintenance fluids orally or by enteral tube, if tolerated.

For more guidance on fluid therapy, see the [NICE guidelines on intravenous fluid therapy in adults](#) and [intravenous fluid therapy in children and young people](#).

Osmotic agents

1.9.3 Do not use glycerol in the management of bacterial meningitis in babies, children, young people and adults.

1.9.4 Do not routinely use other osmotic agents (such as mannitol or hypertonic sodium chloride) in the management of bacterial meningitis in babies, children, young people and adults.

1.9.5 If there are signs of raised intracranial pressure and concerns about brain herniation:

- consider osmotic agents (but not glycerol) as a temporary measure to reduce intracranial pressure
- for adults, get urgent advice from critical care
- for babies, children and young people, get urgent advice from paediatric critical care services.

Intracranial pressure monitoring

1.9.6 Do not routinely use invasive intracranial pressure monitoring in the management of bacterial meningitis in babies, children, young people and adults.

1.9.7 Get specialist advice on intracranial pressure monitoring if there are features of raised intracranial pressure or hydrocephalus.

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on fluid restriction, osmotic agents and intracranial pressure monitoring](#).

Full details of the evidence and the committee's discussion are in the following evidence reviews:

- [evidence review G1: fluid restriction in bacterial meningitis](#)
- [evidence review G2: osmotic agents in bacterial meningitis](#)
- [evidence review G3: intracranial pressure monitoring in bacterial meningitis](#).

1.10 Assessing for immunodeficiency and recurrence risk in people with bacterial meningitis or meningococcal disease

- 1.10.1 Test for HIV in adults with bacterial meningitis or meningococcal disease.
- 1.10.2 Consider testing for HIV in babies, children and young people with bacterial meningitis or meningococcal disease, if they have signs of immunodeficiency or risk factors for HIV.
- 1.10.3 Refer babies, children and young people with pneumococcal meningitis to a paediatric immunology and infectious disease specialist to assess for primary immunodeficiency.
- 1.10.4 For babies and [young children](#) with bacterial meningitis, examine their back and scalp for signs of a sinus tract.
- 1.10.5 For all people with bacterial meningitis or meningococcal disease, take a history of:
- head trauma, surgery or cerebrospinal fluid leak

- immunisations
- medicines, including drugs that suppress the immune system (such as complement inhibitors).

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on assessing for immunodeficiency and recurrence risk in people with bacterial meningitis or meningococcal disease](#).

Full details of the evidence and the committee's discussion are in [evidence review J1: factors associated with recurrent bacterial meningitis](#) and [evidence review J2: factors associated with recurrent meningococcal disease](#).

1.11 Information and support after diagnosis

1.11.1 Early in the management of confirmed bacterial meningitis or meningococcal disease, discuss the following with people and their family members or carers:

- what might happen during the course of the disease
- the uncertainty about their initial prognosis, and when they can expect to know more
- the risk of passing on the infection
- whether their close contacts need to take any preventative measures (for example, for meningococcal meningitis, meningococcal disease or *Haemophilus influenzae* type b)
- visible effects (such as drips and other invasive devices), swelling (for people receiving fluid resuscitation), and how rashes can spread and turn purple
- effects of sedative withdrawal, such as agitation or abnormal neurological behaviour
- the potential short and long-term outcomes, taking account of the severity of their illness and their need for critical care

- how to access support, including contact details of meningitis charities.

1.11.2 Repeat information over time and check the person understands, as they may be distressed and unable to ask questions when they are first diagnosed.

For more guidance on providing information, see the NICE guidelines on:

- [patient experience in adult NHS services](#)
- [babies, children and young people's experience of healthcare](#).

1.11.3 Provide emotional and pastoral support for people and their family members and carers during hospitalisation.

1.11.4 Consider referral for psychological interventions, for people with bacterial meningitis or meningococcal disease who need specialist psychological support.

1.11.5 Before discharge from hospital, explain to the person and their family members or carers:

- how to access support, including contact details of meningitis charities
- what assessments, aftercare and follow-up they will receive (now and long-term)
- any uncertainties about what long-term effects they might experience.

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on information and support after diagnosis](#).

Full details of the evidence and the committee's discussion are in [evidence review K3: information for confirmed bacterial meningitis or meningococcal disease](#) and [evidence review K4: support for confirmed bacterial meningitis or meningococcal disease](#).

1.12 Preparing for hospital discharge

Identifying and managing complications

- 1.12.1 Identify follow-up needs for people who have had bacterial meningitis or meningococcal disease, taking into account potential cognitive, neurological, developmental, orthopaedic, skin, hearing, psychosocial, education, and renal complications.

Cognitive, neurological and developmental complications

- 1.12.2 Refer babies, children and young people for community neurodevelopmental follow-up.
- 1.12.3 Refer children, young people and adults to psychological services for cognitive and psychological support if follow-up needs have been identified.
- 1.12.4 For people who are taking anti-epileptic drugs, refer for a medicines review 3 months after hospital discharge, with a clinician with an interest in epilepsy, an epilepsy specialist nurse, or a neurologist.

Orthopaedic and skin complications

- 1.12.5 For people with acute orthopaedic complications (such as amputation):
- arrange follow-up with an orthopaedic surgeon after discharge
 - consider referral to psychological services.
- 1.12.6 For people with orthopaedic and skin complications:
- coordinate management with tissue viability and community nursing services
 - refer to rehabilitation services for assessment as needed.

Audiological assessment

- 1.12.7 Offer an audiological assessment within 4 weeks of the person being well enough for testing (and preferably before discharge).
- 1.12.8 Offer children, young people and adults with severe or profound deafness an urgent assessment for cochlear implants.

For further guidance on cochlear implants, see the [NICE technology appraisal guidance on cochlear implants for children and adults with severe to profound deafness](#).

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on identifying and managing complications](#).

Full details of the evidence and the committee's discussion are in [evidence review I1: long-term complications and follow-up for bacterial meningitis](#) and [evidence review I2: long-term complications and follow-up for meningococcal disease](#).

Planning for care after discharge

- 1.12.9 For people who have had bacterial meningitis or meningococcal disease, tell their GP (and health visitor and school nurse if relevant), and explain any follow-up plans.
- 1.12.10 Tell the person and their family members or carers who their main point of contact will be after discharge.
- 1.12.11 Document the follow-up plan for managing complications in the discharge summary.
- 1.12.12 The hospital team should coordinate with the following professionals for care after discharge:
- tertiary and primary care and other specialists
 - allied professionals and community teams that will be involved in follow-up

(for example audiology, speech and language therapy, and psychology departments).

Providing information

1.12.13 Tell people who have had bacterial meningitis or meningococcal disease:

- when they are likely to be able to resume:
 - driving (see the [Driver and Vehicle Licensing Agency guidance on assessing fitness to drive](#), including the [advice specific to neurological disorders](#))
 - travel
 - work and education
 - exercise and sports
- that these timings may change, based on the results of their follow-up assessments.

Psychosocial support

1.12.14 Consider referral to psychosocial support for people who have had bacterial meningitis or meningococcal disease and their family members and carers.

Education support

1.12.15 Think about the need for education support for children and young people who have had bacterial meningitis or meningococcal disease. Discuss with their GP. See the [section on further reviews for babies, children and young people](#).

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on planning for care after hospital discharge](#).

Full details of the evidence and the committee's discussion are in the following evidence reviews:

- [evidence review I1: long-term complications and follow-up for bacterial meningitis](#)
- [evidence review I2: long-term complications and follow-up for meningococcal disease](#)
- [evidence review K3: information for confirmed bacterial meningitis or meningococcal disease](#)
- [evidence review K4: support for confirmed bacterial meningitis or meningococcal disease](#).

1.13 Care after hospital discharge

First review

1.13.1 For babies, children and young people who have had bacterial meningitis or meningococcal disease, arrange for a review with a paediatrician at 4 to 6 weeks after discharge from hospital. As part of this review, cover:

- the results of their audiological assessment, and whether cochlear implants are needed
- damage to bones and joints
- skin complications (including scarring from necrosis)
- psychosocial problems (if relevant, see the [NICE guideline on post-traumatic stress disorder](#))
- neurological and developmental problems, in liaison with community child

development services.

1.13.2 For adults who have had bacterial meningitis or meningococcal disease, arrange for a review with a hospital doctor at 4 to 6 weeks after discharge from hospital. As part of this review, cover:

- the results of their audiological assessment (if available at this time), and whether cochlear implants are needed
- damage to bones and joints
- skin complications (including scarring from necrosis)
- psychosocial problems (if relevant, see the [NICE guideline on post-traumatic stress disorder](#))
- neurological problems
- care needs.

Further reviews for babies, children and young people

1.13.3 For babies under 12 months who have had meningitis or meningococcal disease, arrange a review with a paediatrician for 1 year after discharge. At this review, assess for possible late-onset neurodevelopmental, orthopaedic, sensory and psychosocial complications.

1.13.4 Healthcare professionals (such as school nurses, health visitors and GPs) with responsibility for monitoring the health and wellbeing of babies, children and young people should be alert for late-onset complications of bacterial meningitis or meningococcal disease.

1.13.5 Be aware that late-onset complications may not be apparent until transition points (such as starting nursery or school).

1.13.6 For babies, children and young people, community child development services should follow up and assess the risk of long-term neurodevelopmental complications for at least 2 years after discharge.

- 1.13.7 If a neurodevelopmental deficit is identified, refer to the appropriate services (for example, neurodisability services) and agree with them who will be responsible for follow-up, to ensure that nobody misses out on care.
- 1.13.8 Advise family members or carers to get advice from their GP if their child or young person develops possible neurodevelopmental complications more than 2 years after discharge.
- 1.13.9 Advise family members or carers to discuss the following with their child or young person's school:
- their child or young person has had meningitis or meningococcal disease
 - this may affect their learning
 - they may need additional reviews of their educational outcomes and learning needs, even when there have been no known complications.

Return to education or work for adults

- 1.13.10 Advise adults that they may need to arrange a phased return to education or employment.
- 1.13.11 Refer for assessments of any additional needs or adaptations (including driving) if needed.

For guidance on helping people return to work, see the [NICE guideline on workplace health: long-term sickness absence and capability to work](#).

For guidance on rehabilitation for adults, see the [NICE guideline on rehabilitation after critical illness in adults](#).

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on care after hospital discharge](#).

Full details of the evidence and the committee's discussion are in the following evidence reviews:

- [evidence review I1: long-term complications and follow-up for bacterial meningitis](#)
- [evidence review I2: long-term complications and follow-up for meningococcal disease](#)
- [evidence review K4: support for confirmed bacterial meningitis or meningococcal disease](#).

1.14 Recurrent bacterial meningitis and meningococcal disease

Risk factors

1.14.1 Risk factors for recurrent bacterial meningitis are:

- primary or secondary immunodeficiency, including:
 - HIV
 - congenital complement deficiency or acquired inhibition
 - reduced or absent spleen function
 - hypogammaglobulinaemia
- communication between the cerebrospinal fluid and external surface, for example caused by:
 - prior trauma or surgery

- a congenital anomaly.

1.14.2 The risk factor for recurrent meningococcal disease is primary or secondary immunodeficiency, including:

- HIV
- congenital complement deficiency or acquired inhibition
- reduced or absent spleen function.

Management

1.14.3 For people who have had a recurrent episode of bacterial meningitis or meningococcal disease:

- review with a paediatric immunology and infectious disease specialist or an adult infection specialist or immunologist (as appropriate) **and**
- agree which tests, investigations, vaccines and other interventions are needed to prevent re-occurrence.

1.14.4 Test for HIV in babies, children, young people and adults with recurrent bacterial meningitis or meningococcal disease.

1.14.5 For babies and young children with recurrent bacterial meningitis, examine their back and scalp for signs of a sinus tract.

1.14.6 For people with recurrent bacterial meningitis, get specialist radiological advice on investigations for a cerebrospinal fluid leak.

1.14.7 For people with recurrent bacterial meningitis or meningococcal disease, take an immunisation and medicine history, including for drugs that suppress the immune system (such as complement inhibitors).

1.14.8 In people with recurrent meningitis with unconfirmed bacterial cause, consider other causes (for example, Mollaret's lymphocytic meningitis) and get advice

from an infection specialist.

For a short explanation of why the committee made these recommendations and how they might affect practice, see the [rationale and impact section on recurrent bacterial meningitis and meningococcal disease](#).

Full details of the evidence and the committee's discussion are in [evidence review J1: factors associated with recurrent bacterial meningitis](#) and [evidence review J2: factors associated with recurrent meningococcal disease](#).

Terms used in this guideline

This section defines terms that have been used in a particular way for this guideline.

Adults

18 years and over.

Babies

29 days to 1 year (adjusted for gestational age from their due birth date).

Children

1 to 11 years.

Enterobacterales (coliforms)

Enterobacterales (formerly known as Enterobacteriaceae and commonly referred to as 'coliform' bacteria) are a large order of gram-negative bacterial pathogens, including *Escherichia coli* (*E. coli*), *Klebsiella*, *Enterobacter*, *Serratia* and others.

Infection specialist

Microbiologist or infectious diseases specialist.

Older adults

Over 65 years.

Senior clinical decision maker

A 'senior clinical decision maker' for people under 18 is a paediatric or emergency care qualified doctor or equivalent with core competencies in the care of acutely ill children (usually grade ST4 or above).

A 'senior clinical decision maker' for people aged 18 years or over should be a clinician with core competencies in the care of acutely ill patients (usually ST3 or above) or equivalent.

Severe antibiotic allergy

A history of allergy to antibiotics with effects that are clearly likely to be allergic in nature, such as anaphylaxis, respiratory distress or angioedema.

Strongly suspected

Bacterial meningitis can be strongly suspected:

- if the person has the red flag combination of symptoms (see [recommendation 1.1.4](#)) **or**
- based on clinical assessment of the symptoms and signs and risk factors present, for people who do not have the red flag combination.

Meningococcal disease can be strongly suspected:

- if the person has any of the red flag symptoms (see [recommendation 1.1.9](#)) **or**
- based on clinical assessment of the symptoms and signs and risk factors present, for people who do not have any of the red flag symptoms.

Young adults

18 to 25 years.

Young babies

29 days to 3 months (adjusted for gestational age from their due birth date).

Young children

Over 1 year up to 5 years (adjusted for gestational age from their due birth date for children up to 2 years).

Young people

12 to 17 years.

Recommendations for research

The guideline committee has made the following recommendations for research.

1 Long-term outcomes of bacterial meningitis

What are the long-term outcomes after bacterial meningitis in infancy?

For a short explanation of why the committee made this recommendation for research and how it might affect practice, see the [rationale section on identifying and managing complications](#).

Full details of the evidence and the committee's discussion are in [evidence review I1: long-term complications and follow-up for bacterial meningitis](#).

2 Novel diagnostic techniques applied to blood or cerebrospinal fluid

Can novel host biomarker or metagenomic techniques applied to blood or cerebrospinal fluid be used to diagnose bacterial meningitis?

For a short explanation of why the committee made this recommendation for research and how it might affect practice, see the [rationale section on cerebrospinal fluid investigations](#).

Full details of the evidence and the committee's discussion are in [evidence review B3: investigating and diagnosing suspected bacterial meningitis with cerebrospinal fluid parameters](#).

3 Duration of antibiotic treatment for meningitis caused by Enterobacterales (coliforms)

What is the effectiveness of shorter courses of antibiotics (compared with standard duration courses) for treating bacterial meningitis caused by Enterobacterales (coliforms), particularly in newborn babies?

For a short explanation of why the committee made this recommendation for research and how it might affect practice, see the [rationale section on antibiotics for bacterial meningitis in hospital when the causative organism is known](#).

Full details of the evidence and the committee's discussion are in [evidence review E4: antibiotics for bacterial meningitis caused by gram-negative bacilli](#).

4 Intracranial pressure monitoring

In people with bacterial meningitis and impaired consciousness, are clinical outcomes improved if invasive and non-invasive intracranial pressure monitoring is used to guide treatment decisions?

For a short explanation of why the committee made this recommendation for research and how it might affect practice, see the [rationale section on fluid restriction, osmotic agents and intracranial pressure monitoring for confirmed bacterial meningitis](#).

Full details of the evidence and the committee's discussion are in [evidence review G3: intracranial pressure monitoring in bacterial meningitis](#).

5 Corticosteroids for newborn babies with bacterial meningitis

What is the effectiveness of corticosteroids as an adjunct to antibiotic treatment in newborn babies with suspected or confirmed bacterial meningitis?

For a short explanation of why the committee made this recommendation for research and how it might affect practice, see the [rationale section on corticosteroids for bacterial meningitis and meningococcal disease](#).

Full details of the evidence and the committee's discussion are in [evidence review G4: corticosteroids for treatment of bacterial meningitis](#).

Rationale and impact

These sections briefly explain why the committee made the recommendations and how they might affect practice.

Recognising bacterial meningitis and meningococcal disease

[Recommendations 1.1.1 to 1.1.3](#)

Why the committee made the recommendations

Bacterial meningitis and meningococcal disease can be fatal if treatment is delayed. They are also difficult to diagnose, as they can present with non-specific symptoms and signs, and can be difficult to distinguish from other infections. The committee used their expertise and the available evidence to highlight the most important risk factors and specific and non-specific symptoms and signs to take into account when considering a diagnosis, to help reduce the chance that bacterial meningitis and meningococcal disease are missed.

How the recommendations might affect practice

The recommendations are in line with current practice and they should not have a significant resource impact. The recommendations will help healthcare professionals recognise and diagnose bacterial meningitis and meningococcal disease earlier, and earlier treatment will lead to reduced costs.

[Return to recommendations](#)

When to suspect bacterial meningitis

[Recommendations 1.1.4 to 1.1.8](#)

Why the committee made the recommendations

There was evidence on the sensitivity and specificity of the following symptoms, for a diagnosis of bacterial meningitis:

- fever was overall moderately to highly sensitive, but not specific
- headache had mixed evidence, ranging from non-significant to moderate sensitivity and specificity
- neck stiffness was overall moderately sensitive and specific
- altered level of consciousness or cognition was overall moderately sensitive and specific.

In the committee's experience, people with all of these symptoms and signs together are highly likely to have bacterial meningitis. However, the committee emphasised that bacterial meningitis should not be ruled out just because a person does not have one or more of these signs or symptoms. Bacterial meningitis can present in different ways, particularly in babies and older adults or if people are presenting early in the condition.

The other symptoms and signs listed are based on the evidence and the committee's knowledge and experience. Outside of the red flag combination, the evidence was not clear enough for the committee to rank the symptoms and signs in order of importance. However, in the committee's experience, the more symptoms and signs present, the more likely it is that the person has bacterial meningitis.

The evidence on risk factors was limited, because it came from a single study looking at perinatal risk factors (such as low birth weight) for bacterial meningitis. In the absence of evidence, the committee specified risk factors based on their knowledge and experience. Some of the risk factors are also indirect indicators of potential immune deficiency (including family history and a previous episode of meningitis or meningococcal disease).

How the recommendations might affect practice

The recommendations are in line with current practice and they should not have a significant resource impact. The recommendations will help healthcare professionals recognise and diagnose bacterial meningitis earlier. This will allow for earlier treatment, which will reduce costs through lower rates of death and complications.

[Return to recommendations](#)

When to suspect meningococcal disease

[Recommendations 1.1.9 to 1.1.15](#)

Why the committee made the recommendations

Evidence showed that these symptoms both had at least moderate sensitivity and specificity for a diagnosis of meningococcal disease:

- a haemorrhagic, non-blanching rash with lesions larger than 2 mm (purpura)
- a rapidly progressive and/or spreading rash.

There was also evidence that some symptoms and signs of meningitis (including neck pain or stiffness, photophobia, and a composite clinical factor of signs or symptoms of meningism) were also moderately or highly specific for a diagnosis of meningococcal disease. In the committee's experience, when a person has symptoms and signs that could indicate meningitis or meningococcal disease, they are more likely to have meningococcal disease if they also have a non-blanching petechial or purpuric rash.

While a non-blanching petechial or purpuric rash is a commonly known sign of meningococcal disease (and this is supported by the evidence), the committee were aware based on their knowledge and experience that not everyone with meningococcal disease will have a rash. They highlighted this issue to avoid people being misdiagnosed and to avoid delays to treatment.

The committee gave advice on finding rashes, because in their experience, not all healthcare professionals are aware of these issues.

The other symptoms and signs listed are based on the evidence and the committee's knowledge and experience. Outside of the red flag symptoms, the evidence was not clear enough for the committee to rank the symptoms and signs in order of importance.

The risk factors listed are based on evidence and the committee's knowledge and experience. Some of the risk factors are also indirect indicators of potential immune deficiency (including family history and a previous episode of meningitis or meningococcal

disease).

How the recommendations might affect practice

The recommendations are in line with current practice and they should not have a significant resource impact. The recommendations will help healthcare professionals recognise and diagnose meningococcal disease earlier. This will allow for earlier treatment, which will reduce costs through lower rates of death and complications.

[Return to recommendations](#)

Safety netting and alternative causes

[Recommendations 1.1.16 and 1.1.17](#)

Why the committee made the recommendations

Because bacterial meningitis and meningococcal disease are difficult to diagnose or distinguish from other conditions, the committee agreed that it is important to provide safety netting. Based on their knowledge and experience, they made recommendations to cover people who are unlikely to have bacterial meningitis or meningococcal disease, but who need monitoring for changes to symptoms. They also highlighted other serious conditions with similar symptoms and signs.

How the recommendations might affect practice

The recommendations are in line with current practice and they should not have a significant resource impact.

There will be a level of uncertainty even in people who are unlikely to have bacterial meningitis or meningococcal disease. Safety netting helps mitigate the potential harms and costs of missed infections, and harms and costs from other serious conditions with similar symptoms and signs.

[Return to recommendations](#)

Transfer to hospital and antibiotics before arrival at hospital

Recommendations 1.2.1 to 1.2.6

Why the committee made the recommendations

Delay to treatment for bacterial meningitis or meningococcal disease can be fatal, or cause serious complications. Because of this, the committee agreed (based on their knowledge and experience) that people with suspected or strongly suspected bacterial meningitis or meningococcal disease should be transferred to hospital as an emergency.

For suspected bacterial meningitis, there is evidence showing no clear benefit from pre-hospital antibiotics (in terms of all-cause mortality, long-term neurological impairment, or functional impairment). Giving antibiotics before transfer to hospital would also affect the results of cerebrospinal fluid tests and some blood tests. In line with this evidence, the committee agreed that antibiotics should not normally be given outside of hospital, unless there is a clinically significant delay in transfer to hospital and bacterial meningitis is strongly suspected. The committee could not give a timeframe for what delay counts as clinically significant, because there was no evidence on this point.

Similarly, evidence for meningococcal disease did not show clear benefits from pre-hospital antibiotics, and giving antibiotics before hospital would also affect blood test results. However, given the rapid progression and seriousness of meningococcal disease, the committee agreed that pre-hospital antibiotics should be given as soon as possible when the disease is strongly suspected.

While the committee recommended antibiotics outside of hospital in some circumstances, they highlighted that the priority for both bacterial meningitis and meningococcal disease should be the transfer to hospital. This is so that urgent testing can be done to get a clear diagnosis and start the correct treatment as soon as possible.

When antibiotics need to be given outside of hospital, ceftriaxone is the preferred option because it is a more active agent. However, it is less commonly available outside of hospital. Therefore, benzylpenicillin is also recommended because it is commonly available and practical to use outside of hospital.

How the recommendations might affect practice

The recommendations are in line with current practice. Benzylpenicillin is commonly available outside of hospital. Ceftriaxone use is rarer outside of hospital, but it may be available in some settings.

[Return to recommendations](#)

Information and support for people with suspected bacterial meningitis or meningococcal disease

[Recommendations 1.3.1 and 1.3.2](#)

Why the committee made the recommendations

The recommendations on what to discuss with people with suspected bacterial meningitis or meningococcal disease are based on evidence and the committee's knowledge of:

- the issues that matter most to people in this situation **and**
- what people need to know if they are sent home with an unconfirmed diagnosis.

There was evidence on accessible, person-centred communication and sharing information. However, this is covered by existing recommendations in the NICE guidelines on patient experience in the NHS.

This guideline also makes [recommendations on information and support after diagnosis](#).

How the recommendations might affect practice

The recommendations are good practice, although they are not currently implemented everywhere. The list of issues to discuss is short and should not take up much time, as the focus at this stage is diagnosis and treatment.

[Return to recommendations](#)

Timing of investigations and antibiotics for

bacterial meningitis

Recommendation 1.4.1

Why the committee made the recommendation

As suspected bacterial meningitis is a medical emergency, the committee agreed (based on their knowledge and experience) that a senior clinical decision maker should perform an initial assessment and ensure that investigations are done promptly. This will prevent unnecessary delays to the first dose of antibiotics (if this was not given before arrival at hospital).

How the recommendation might affect practice

Hospitals may need to streamline their processes so that blood tests can be done within the 1-hour timeframe for giving antibiotics.

[Return to recommendation](#)

Bacterial throat swabs and blood tests for bacterial meningitis

Recommendations 1.4.3 to 1.4.5

Why the committee made the recommendations

A bacterial throat swab can provide information about the strain of *Neisseria meningitidis*. The Public Health England guidance on managing meningococcal disease recommends taking a bacterial throat swab for suspected meningococcal disease to provide information about the infecting strain, to guide management of cases, contacts and outbreaks. The committee extended this to people with suspected bacterial meningitis because *Neisseria meningitidis* is a potential cause of meningitis.

All of the evidence was based on individual blood tests and the committee agreed that none of these blood tests alone would be sufficient to make a diagnosis of bacterial meningitis, nor should any of these tests be used to rule out bacterial meningitis. However, blood tests are an important tool for gathering information to inform the diagnosis, when

used alongside clinical features and lumbar puncture results. The recommended blood tests are all simple, relatively cheap, and widely used in current practice.

Both C-reactive protein (CRP) and procalcitonin (PCT) were shown to be useful tests for bacterial meningitis. However, PCT is only recommended if CRP is not available, because PCT is more expensive and the evidence did not demonstrate a large difference in diagnostic accuracy.

How the recommendations might affect practice

Bacterial throat swab, CRP, PCT, white cell count, blood culture, and polymerase chain reaction (PCR) are routinely used in current practice. Hospitals may need to streamline their processes so that blood tests can be done within the 1-hour timeframe for giving antibiotics.

[Return to recommendations](#)

Neuroimaging

[Recommendations 1.4.6 to 1.4.8](#)

Why the committee made the recommendations

Evidence showed that performing a lumbar puncture without waiting for a CT scan led to people receiving antibiotic treatment sooner. This may reduce the rates of:

- mortality
- neurological problems
- hearing problems
- functional impairment.

While most people with suspected meningitis do not need imaging before a lumbar puncture, neuroimaging should be performed for people with risk factors for an evolving space occupying lesion. Imaging should also be performed for people with the following features of raised intracranial pressure, due to the risk of brain herniation following lumbar puncture:

- seizures
- posturing
- abnormal pupillary reactions
- reduced consciousness.

Based on their knowledge and experience, the committee defined the change in consciousness that would indicate neuroimaging was needed. They also highlighted that antibiotics should be given and bloods taken before imaging, since it can take time for neuroimaging to be completed.

How the recommendations might affect practice

These recommendations will result in less neuroimaging being performed.

[Return to recommendations](#)

Lumbar puncture

[Recommendation 1.4.2](#) and [recommendations 1.4.9 to 1.4.13](#)

Why the committee made the recommendations

Lumbar puncture is the only test that can directly confirm a diagnosis of bacterial meningitis.

Antibiotics can affect the results of cerebrospinal fluid tests, so lumbar puncture needs to be performed before antibiotics when possible. The committee did not recommend a specific timeframe for performing lumbar puncture because they were concerned that it would be interpreted as a hard cutoff. The key timeframe is the 1-hour timeframe for giving antibiotics, but clinical judgement is needed for decisions on how to fit lumbar puncture around this. For example, for some people, it may be safe to delay the antibiotics by slightly longer than 1 hour, if this would allow a lumbar puncture to be performed first.

The committee used their experience to highlight situations that need treating or stabilising before a lumbar puncture, because these are potentially life-threatening and present a greater risk than delayed meningitis investigations.

How the recommendations might affect practice

Lumbar punctures can often be performed more quickly on acute medical wards than in emergency departments. Because of this, hospitals may need to be able to urgently transfer people with suspected bacterial meningitis out of emergency departments (following stabilisation). Hospitals may also need to streamline their processes so that acute medical wards can perform lumbar punctures within the 1-hour timeframe for giving antibiotics.

[Return to recommendation 1.4.2](#)

[Return to recommendations 1.4.9 to 1.4.13](#)

Cerebrospinal fluid investigations

[Recommendations 1.4.14 to 1.4.19](#)

Why the committee made the recommendations

There was evidence on various cerebrospinal fluid investigations for diagnosing bacterial meningitis:

- studies looked at multiple thresholds for white cell count, finding that it was at least moderately sensitive and specific at most thresholds, and very specific and sensitive at some thresholds
- overall, the evidence showed that protein concentration was at least moderately sensitive and specific
- gram staining and culture was very specific for identifying all causes of bacterial meningitis
- there was a large, consistent body of evidence showing that PCR was at least moderately sensitive and very specific for identifying particular causes of bacterial meningitis.

The committee highlighted that cerebrospinal fluid cell counts, total protein and glucose concentrations are important for clinical decision making and to guide antibiotic treatment, and agreed that these results should be available within 4 hours.

It is important to look at the whole clinical picture and take a full clinical history, including maternal history for babies aged 28 days or under. This is because there are factors that may reduce the reliability of cerebrospinal fluid investigations. Based on their knowledge and experience the committee highlighted the most important of these factors.

Age-appropriate threshold values for cerebrospinal fluid should be used.

The committee highlighted the need to consider alternative diagnoses because there could be serious consequences if a potentially treatable alternative cause is missed.

There are new diagnostic techniques currently in development, such as host biomarker or metagenomic techniques. These may be able to address some of the problems with the current gold standards for diagnosing bacterial meningitis, including the time taken to receive results, the need to start antibiotic treatment before confirming a diagnosis, and the difficulties with differential diagnoses. As these techniques have not yet been sufficiently validated for clinical use, the committee made a [recommendation for further research on novel diagnostics](#).

How the recommendations might affect practice

The recommendations largely support current practice, and they should not have a significant resource impact.

PCR was not included as part of cerebrospinal fluid investigations in the 2010 guideline, but it has since become standard practice in most hospitals.

[Return to recommendations](#)

Investigating suspected meningococcal disease in hospital

[Recommendations 1.5.1 to 1.5.5](#)

Why the committee made the recommendations

As suspected meningococcal disease is a medical emergency, the committee agreed (based on their knowledge and experience) that a [senior clinical decision maker](#) should

perform an initial assessment and ensure that investigations are done promptly. This will prevent unnecessary delays to the first dose of antibiotics (if this was not given before arrival at hospital).

A bacterial throat swab can provide information about the strain of *Neisseria meningitidis*. The [Public Health England guidance on managing meningococcal disease](#) recommends taking a bacterial throat swab for suspected meningococcal disease to provide information about the infecting strain, to guide management of cases, contacts and outbreaks.

Blood tests (along with clinical features) are the main way to diagnose meningococcal disease. The recommended tests are also all simple, relatively cheap, and widely used in current practice.

PCT is only recommended if CRP is not available. This is because it is more expensive and the evidence did not demonstrate a large difference in diagnostic accuracy.

It is important not to make a diagnosis on the basis of an individual blood test or to rule out meningococcal disease based on a normal CRP, PCT or white blood cell count alone, because none of these tests were shown to be both very sensitive and very specific.

The evidence for the diagnostic accuracy of blood culture or whole-blood diagnostic PCR were not reviewed, because these tests were used as reference standards.

How the recommendations might affect practice

CRP, PCT, white cell count, lactate, blood culture, and PCR are routinely used in current practice. Hospitals may need to streamline their processes so that blood tests can be done within the 1-hour timeframe for giving antibiotics.

[Return to recommendations](#)

Antibiotics for bacterial meningitis in hospital

[Recommendations 1.6.1 to 1.6.9](#)

Why the committee made the recommendations

For adults in hospital, there was evidence that giving antibiotics as soon as bacterial meningitis is suspected reduces mortality, compared with giving antibiotics later. The evidence also showed that giving antibiotics early reduced functional impairment, but only when compared against delays of longer than 6 hours.

For babies, children, or young people, there was no evidence that met the review criteria. The committee agreed, based on the evidence for adults as well as their clinical knowledge and expertise, that there were similar risks of adverse outcomes for these groups if antibiotics were delayed.

The 1-hour timeframe for starting antibiotics in hospital is based on the committee's expertise, and on the well-recognised principle of the 'golden hour' for optimal treatment of life-threatening emergencies such as meningitis. Blood tests and lumbar puncture should also be completed within this hour (when it is safe and practical to do so), so that samples can be taken before antibiotics are started in hospital.

The committee recommended getting infection specialist advice for bacterial meningitis, because there may be concerns about antibiotic resistance or uncertainty about treatment in specific people (for example, because of comorbidities). This is particularly important for suspected or confirmed cephalosporin-resistant bacterial meningitis, because alternative antibiotics may be needed and there is no evidence for specific antibiotics in this situation.

The evidence on specific antibiotics was very limited (low or very low quality evidence, with small numbers of participants). The committee recommended intravenous ceftriaxone based on their knowledge and experience. Ceftriaxone is a broad-spectrum antibiotic that can be used to treat the most common infective organisms. This treatment is in line with current practice and the BNF and BNFC. There are also potential practical and cost benefits with ceftriaxone, as it can be given once a day. Cefotaxime is recommended as an alternative because ceftriaxone is contraindicated in some circumstances for premature babies. This recommendation is also in line with the BNFC.

There was no evidence on the effectiveness of antibiotics for *Listeria monocytogenes* that met the review criteria. Based on the committee's clinical knowledge and experience, listeria is not susceptible to ceftriaxone or cefotaxime. The committee recommended amoxicillin for people with risk factors for listeria, because amoxicillin is recommended by

the BNF and the BNFC. In the committee's experience, co-trimoxazole can also be beneficial, particularly with bacteraemic or septic illness. However, the committee recommended getting infection specialist advice before using co-trimoxazole, because of the associated risks and monitoring requirements.

The committee were concerned about the overuse of aciclovir. In their experience it is frequently prescribed for suspected meningitis, but it is only beneficial for herpes simplex encephalitis. The committee agreed that aciclovir should only be given when herpes simplex encephalitis is strongly suspected.

The evidence showed no difference between short and long courses of ceftriaxone for bacterial meningitis (4 days compared with 10 days, 7 days compared with 10 days, and 4 to 7 days compared with 8 to 14 days). Given this evidence, the committee recommended short courses of antibiotics.

In the committee's experience, the results of confirmatory tests could be available within 2 to 3 days. It is current practice to continue empirical antibiotic treatment until the causative organism is identified or an alternative diagnosis is confirmed.

The committee highlighted that the UK Health Security Agency should be notified of any suspected cases of meningococcal meningitis or other meningococcal disease.

How the recommendations might affect practice

The guideline recommends shorter courses of antibiotics than the courses used in current practice.

Hospitals may need to streamline their processes so that blood tests and lumbar puncture can be done within the 1-hour timeframe for giving antibiotics.

[Return to recommendations](#)

Antibiotics for bacterial meningitis in hospital, when the causative organism is known

[Recommendations 1.6.10 to 1.6.15](#)

Why the committee made the recommendations

Given the limitations of the evidence (for example, very low quality evidence and small numbers of participants), the committee recommended intravenous ceftriaxone for most causative organisms, based on their knowledge and experience. Ceftriaxone is a broad-spectrum antibiotic that can be used to treat the most common infective organisms. This treatment is in line with current practice and the BNF and the BNFC. There are also practical and cost benefits with ceftriaxone, as it only needs to be given once a day. Cefotaxime is recommended as an alternative because ceftriaxone is contraindicated in some circumstances. This recommendation is also in line with the BNFC.

On treatment length, the evidence showed no difference between short and long courses of ceftriaxone for *Haemophilus influenzae* type b meningitis or meningococcal meningitis (5 days compared with 10 days). For other organisms, there was no evidence that met the review criteria. Given the limitations of the evidence, the committee recommended treatment lengths based on their knowledge, experience and on current practice.

There was no evidence on the effectiveness of antibiotics for *Listeria monocytogenes* that met the review criteria. The committee recommended amoxicillin or ampicillin because these were recommended in the 2010 guideline (based on the knowledge and experience of the 2010 committee). In the 2024 committee's experience, co-trimoxazole can also be beneficial, particularly with bacteraemic or septic illness. However, the committee recommended getting infection specialist advice before using co-trimoxazole, because of the associated risks and monitoring requirements.

Standard treatment duration for meningitis caused by Enterobacterales (coliforms) is at least 21 days. However, this is not evidence-based and may be based on the principle of providing 14 days of antibiotics after sterilisation of cerebrospinal fluid. As third-generation cephalosporins are associated with more rapid sterilisation, the committee made a [recommendation for research on the effectiveness of shorter courses of antibiotics for meningitis caused by Enterobacterales \(coliforms\)](#).

How the recommendations might affect practice

The recommendations are in line with current practice.

[Return to recommendations](#)

Antibiotic allergy with bacterial meningitis

Recommendation 1.6.16

Why the committee made the recommendation

There was no evidence specific to meningitis on antibiotics for people with an antibiotic allergy, so the committee made recommendations based on their knowledge and experience.

Ceftriaxone is still recommended for non-severe allergies because cephalosporin-induced anaphylaxis is rare.

For people with risk factors for *Listeria monocytogenes* and a non-severe allergy, the committee recommended co-trimoxazole in addition to ceftriaxone or cefotaxime, because this is in line with current practice. (Risk factors for *Listeria monocytogenes* include being very old or very young, pregnancy, cancer, kidney disease, liver disease, diabetes, alcohol misuse, and taking drugs that suppress the immune system.)

For people with a severe allergic reaction, the committee recommended chloramphenicol for most causative organisms or when the cause is unknown, because this is in line with current practice. They specified co-trimoxazole and chloramphenicol for people with risk factors for *Listeria monocytogenes* because this is in line with current practice and the BNF.

How the recommendation might affect practice

The recommendations are in line with current practice, and they should not have a significant resource impact.

[Return to recommendation](#)

Antibiotics for meningococcal disease in hospital

Recommendations 1.7.1 to 1.7.3

Why the committee made the recommendations

Ceftriaxone is recommended for meningococcal disease because:

- evidence reviewed for the 2010 guideline showed that it was effective **and**
- evidence reviewed for the 2024 guideline showed that ceftriaxone may reduce necrotic skin lesions when compared with benzylpenicillin sodium.

On duration of antibiotics, there was no evidence that met the review criteria. The committee recommended treatment lengths based on their knowledge, experience and on current practice.

For antibiotic allergy, there was no evidence that met the review criteria, so the committee made recommendations based on their knowledge and experience. Ceftriaxone is still recommended for non-severe allergies because cephalosporin-induced anaphylaxis is rare, and when compared with chloramphenicol the balance of risks and benefits for ceftriaxone is favourable in most people with non-severe allergy. For people with a severe allergic reaction, the committee recommended chloramphenicol because this is in line with current practice.

How the recommendations might affect practice

The recommendations are in line with current practice.

[Return to recommendations](#)

Corticosteroids for bacterial meningitis and meningococcal disease

[Recommendations 1.8.1 to 1.8.7](#)

Why the committee made the recommendations

Corticosteroids for bacterial meningitis

There was evidence of benefit from high-dose dexamethasone:

- in adults, it reduced mortality and hearing impairment
- in babies, children and young people, it reduced hearing impairment.

In most of the studies reviewed, corticosteroids were given before or with antibiotics. Nobody in the studies received corticosteroids more than 12 hours after antibiotics. The committee agreed with the timings used in the studies, but they highlighted that antibiotics should not be delayed just so they can be given at the same time as corticosteroids.

In current practice, corticosteroids are not given to people who started antibiotics more than 12 hours earlier. However, there was no evidence for or against giving corticosteroids more than 12 hours after starting antibiotics, and in the committee's experience there are situations when this would be beneficial. Because there was no evidence, decisions would have to be made on an individual basis, and the committee recommended getting infection specialist advice to help with this.

The committee were aware that in practice, dexamethasone is used in people over 3 months of age. The committee were not aware of any evidence that supports or refutes the use of dexamethasone in children between 28 days and 3 months. In the absence of evidence, the committee agreed that infection specialist advice should be sought because there is less certainty around the balance of benefits and harms in this group.

The evidence for use of corticosteroids in newborn babies aged 28 days or under was limited and very low quality. The committee agreed that it was not appropriate to extrapolate from the evidence for older groups, because the range of causative organisms is different and the impact these have on the developing brain may not be the same. The committee agreed that more evidence was needed for this particular population, so they made a recommendation for research to investigate the effectiveness of corticosteroids for newborn babies with suspected or confirmed bacterial meningitis.

Corticosteroids for meningococcal disease

There was evidence that high-dose dexamethasone increased the risk of mortality in babies, children and young people with meningococcal disease. This evidence was limited and very low quality.

There was no evidence for high- or low-dose dexamethasone in adults with meningococcal disease. The committee agreed to extend the recommendations to cover

this group, based on their clinical expertise and the evidence of a lack of benefit for other groups.

The committee agreed that corticosteroids (including dexamethasone) should not routinely be given to people with meningococcal disease. However, low-dose corticosteroids may still be beneficial for people with meningococcal septic shock that are not responding to high-dose vasoactive agents.

How the recommendations might affect practice

Corticosteroids for bacterial meningitis

High-dose corticosteroids are part of routine practice for strongly suspected and confirmed bacterial meningitis. However, they are not currently started more than 12 hours after people have started taking antibiotics.

Corticosteroids for meningococcal disease

The recommendations are in line with current practice.

[Return to recommendations](#)

Fluid restriction, osmotic agents and intracranial pressure monitoring for confirmed bacterial meningitis

[Recommendations 1.9.1 to 1.9.7](#)

Why the committee made the recommendations

Fluid restriction for bacterial meningitis

For babies over 28 days, children and young people, there was a small amount of evidence comparing fluid restriction with routine maintenance fluids. This evidence showed that fluid restriction reduces pulmonary and facial oedema. However, it also increases rates of neurological impairment and epilepsy. There was no evidence in adults. However, the

committee extended the recommendations to cover these groups because they agreed the risks were likely to be the same, based on their knowledge and experience.

The committee were particularly concerned about the increased rate of neurological impairment, as this could be the most important clinical outcome. Based on the evidence and their knowledge and experience, the committee agreed not to recommend routine fluid restriction for bacterial meningitis. They specified 'routine' because they did not want to stop healthcare professionals from restricting fluids in people with fluid overload.

There are potential complications to providing fluids intravenously, and in the committee's experience, people with bacterial meningitis can often tolerate oral or enteral fluids. Because of this, the committee recommended providing fluids orally or by enteral tube when possible.

Osmotic agents for bacterial meningitis

There was limited evidence in children and babies comparing osmotic agents with placebo or no intervention for raised intracranial pressure. For adults, no evidence met the review criteria.

The committee were concerned that osmotic agents could cause increased mortality. This was based on uncertainty around the estimated effects on mortality in the studies they reviewed, and on the results of the Ajdukiewicz 2011 study showing a higher rate of mortality in adults who had glycerol compared with placebo.

The Ajdukiewicz study was not reviewed as part of the 2024 guideline update, because most of the study population were immunocompromised, and this guideline does not cover people with known immunodeficiency. However, despite the differences between the study population and the guideline population, the committee believed the study needed to be taken into account when making recommendations because any evidence of increased mortality is a serious concern.

Given this evidence, the committee recommended against any use of glycerol in the management of bacterial meningitis. They made a different recommendation for other osmotic agents because the evidence on mortality was less clear for these, and in the committee's experience osmotic agents can be useful when dealing with signs of raised intracranial pressure and concerns about brain herniation.

Intracranial pressure monitoring for bacterial meningitis

There was limited evidence in children, young people and adults comparing intracranial pressure monitoring with no intervention. This evidence showed that intracranial pressure monitoring reduced all-cause mortality in adults. However, this evidence came from 1 study, and a high proportion of the study population was immunosuppressed. As people with immune deficiency are not covered by this guideline, the evidence was only indirectly applicable.

In addition to the limitations of the evidence, intracranial pressure monitoring is an invasive procedure. Because of these factors, the committee recommended against its routine use for all people. They specified 'routine use', because intracranial pressure monitoring may still be beneficial for use in people with bacterial meningitis who have features of raised intracranial pressure or hydrocephalus.

The committee noted that the conventional methods for intracranial pressure monitoring are invasive, associated with important risks, costly, and usually only available in specialist hospitals. The committee made a recommendation for further research to assess the clinical and cost effectiveness of management guided by novel and non-invasive intracranial pressure monitoring.

How the recommendations might affect practice

Fluid restriction for bacterial meningitis

Fluid restriction is not part of routine practice, although it may be used for people with fluid overload.

Osmotic agents for bacterial meningitis

Osmotic agents are not part of routine practice, although they may be used in people with raised intracranial pressure.

Intracranial pressure monitoring for bacterial meningitis

Intracranial pressure monitoring is not part of routine practice, although it may be used for people with raised intracranial pressure or hydrocephalus.

[Return to recommendations](#)

Assessing for immunodeficiency and recurrence risk in people with bacterial meningitis or meningococcal disease

[Recommendations 1.10.1 to 1.10.5](#)

Why the committee made the recommendations

The committee had concerns about the reliability of the evidence, because the sample sizes were not large enough to detect rare events and because people with known immunodeficiency will often receive interventions to prevent recurrent infections. Because of this, the committee used their knowledge and expertise to make recommendations.

The committee agreed that:

- people with HIV have a higher risk of pneumococcal infections and invasive meningococcal disease
- the prevalence of HIV is higher in people with bacterial meningitis
- primary immunodeficiency is present in 8% to 26% of children with invasive pneumococcal disease.

Based on this, the committee recommended HIV testing for adults. Many risk factors for HIV are less likely to be relevant to babies, children and young people, so they do not need to be routinely tested unless there are signs of immunodeficiency and other risk factors.

The committee agreed that referral to specialists was needed for babies, children and young people with pneumococcal meningitis, because this disease may indicate a lack of immune response to pneumococcal vaccination and may be associated with primary immune deficiencies. Adults were not included in this recommendation because there was no evidence of increased rates of primary immunodeficiency in adults with invasive pneumococcal disease.

Some anatomical factors increase the risk of bacterial meningitis (see the explanation of the recommendations on risk factors in the rationale section on when to suspect bacterial

meningitis). The committee agreed that people should be checked for these factors (including signs of a sinus tract), to assess whether they may need intervention to prevent future episodes.

How the recommendations might affect practice

Testing for HIV in adults with a serious infection is in line with current practice. Testing for babies, children and young people is not, but the group who need testing is likely to be small so the resource impact will be minimal.

Other recommendations are in line with current practice.

[Return to recommendations](#)

Information and support after diagnosis

[Recommendations 1.11.1 to 1.11.5](#)

Why the committee made the recommendations

The committee made recommendations based on evidence on the views of parents and carers, and based on their knowledge and experience. The themes in the evidence were consistent for both bacterial meningitis and for meningococcal disease, so the committee made recommendations that apply to both conditions.

The committee emphasised the need to discuss the issues covered in the recommendations with people with bacterial meningitis or meningococcal disease, to give them the chance to ask questions, and to repeat information over time. This is because people may be distressed and unable to ask questions or understand information when they are first admitted to hospital.

Emotional and pastoral support is recommended because of the severe impact meningitis can have on a person. Likewise, some people will experience prolonged distress and would benefit from psychological interventions.

The committee also wanted to ensure that people knew how to get support after leaving hospital, because they will likely need follow-up assessments and aftercare for weeks or

months after discharge.

How the recommendations might affect practice

The recommendations largely reflect current practice and they should not have a significant resource impact.

[Return to recommendations](#)

Identifying and managing complications

[Recommendations 1.12.1 to 1.12.8](#)

Why the committee made the recommendations

Evidence showed that meningitis and meningococcal disease can result in a range of long-term complications, such as:

- learning disability, which can lead to speech and language problems in babies, as well as poor educational attainment or the need for special educational assistance in babies and children
- long-term behavioural problems and problems with adjustment
- psychological distress
- acute orthopaedic and skin complications (with meningococcal disease)
- hearing problems, including acute deafness.

Most of the evidence concerned long-term complications for babies, children, young people and young adults. However, the committee agreed that it was reasonable to extrapolate much of this evidence to adults, because meningitis can have similar impacts on people regardless of age.

Based on this evidence, the committee agreed that people with bacterial meningitis or meningococcal disease should not be discharged from hospital until follow-up needs have been identified and planned for, and until certain assessments have been planned or completed. The committee did recognise that certain tests, like an audiological

assessment, might not be possible until after discharge (although testing before discharge would be preferable).

The evidence for epilepsy as a long-term complication was mixed. For example, there was evidence of an increase in children who have had meningitis being admitted as inpatients because of epilepsy, but no evidence of increased use of outpatient epilepsy services in the same population. The committee were also concerned about unnecessary long-term use of anti-epileptic drugs. They recommended a 3-month review to check whether the seizures were a short-term effect of the illness.

The evidence on long-term complications after bacterial meningitis in newborn babies was limited to a single, small study. The committee agreed that quantifying the long-term complications of bacterial meningitis is important, to allow follow-up to be arranged for those at risk and to help with prioritising treatment and prevention strategies. To address this, the committee made a [recommendation for research to investigate long-term outcomes after bacterial meningitis in infancy](#).

How the recommendations might affect practice

It is routine practice to identify possible follow-up needs before discharge and to make referrals when needed. There is some variation in follow-up for adults, but this should not have a significant resource impact given the small numbers of people affected.

[Return to recommendations](#)

Planning for care after discharge

[Recommendations 1.12.9 to 1.12.15](#)

Why the committee made the recommendations

There was evidence on the views and experiences of families and carers of people who have had meningitis. The committee built on this with their own expertise. They recommended coordination with other professionals and services because this will ensure that follow-up care and support meets the person's needs, and will potentially reduce the impact of long-term complications.

Referral for psychosocial support is recommended because of the potential psychological impact of meningitis. It may need to be arranged after discharge because the impact may not be apparent immediately.

How the recommendations might affect practice

It is routine practice to make referrals and plan for care after discharge, and to inform GPs and other key professionals of any follow up needs. There is some variation in follow-up for adults, but this should not have a significant resource impact given the small numbers of people affected.

[Return to recommendations](#)

Care after hospital discharge

[Recommendations 1.13.1 to 1.13.11](#)

Why the committee made the recommendations

The committee agreed areas to cover in the post-discharge review based on the evidence of the long-term complications associated with meningitis (see the [explanation of the recommendations on identifying and managing complications](#)).

The review should happen at 4 to 6 weeks after discharge so that short-term effects of the illness can be ruled out and long-term issues can be identified early enough to make prompt referrals. The results of hearing tests may not be available at this point (for example, if illness interferes with the timing of the test), but the overall review should not be delayed if this is the case.

The evidence showed particular long-term complications for babies, children and young people. The committee used their own knowledge and experience to make recommendations on further tests and reviews for this group. These tests and reviews are important for identifying late-onset complications and developmental issues as children and young people grow up.

The tests and reviews recommended will involve staff working in multiple services, across health and education. The committee made a recommendation on coordinating follow-up,

to avoid situations where professionals assume other services are responsible and people do not receive proper care as a result.

The evidence suggested that meningitis can increase the risk of poor educational outcomes, that the impact of long-term complications may not always be apparent, and that children and younger people who are seen to be underachieving could be achieving more if they had more specific support. This guideline does not cover education settings, so the committee advised parents and carers to discuss educational complications with their child or young person's school.

No evidence was identified relating to a phased return to work. However, based on their knowledge and experience the committee recommended that healthcare professionals discuss this with people, so they could plan for their return to work.

How the recommendations might affect practice

It is routine practice to review people who have had meningitis or meningococcal disease for long-term complications after hospital discharge. There is some variation in follow-up for adults, but this should not have a significant resource impact given the small numbers of people affected.

[Return to recommendations](#)

Recurrent bacterial meningitis and meningococcal disease

[Recommendations 1.14.1 to 1.14.8](#)

Why the committee made the recommendations

Risk factors

Evidence showed that some anatomical factors increased the risk of recurrent bacterial meningitis (such as a cerebrospinal fluid leak). For most immunological factors, there was no evidence that met the review criteria.

The committee had concerns about the reliability of the anatomical and immunological

evidence, because the studies only looked at a very small number of people for some risk factors and for recurrent bacterial meningitis in general. Because of this, the committee made recommendations about the risk factors they believed to be most important, based on their knowledge and experience.

Management

There was no evidence, so the committee made recommendations based on their knowledge and experience. They recommended a specialist review to decide which investigations, treatments and immunisations were needed to help prevent further recurrence.

The committee made recommendations on HIV testing, immunisation and medicine history, and sinus tract examination, in line with the recommendations on assessing for immunodeficiency and recurrence risk (see the [explanation of the recommendations on assessing for immunodeficiency and recurrence risk](#)). They recommended HIV testing for all age groups after a recurrent episode, because at this point there is an increased chance of immunodeficiency.

The committee also highlighted the possibility of other rare causes of recurrent meningitis.

How the recommendations might affect practice

Risk factors

The recommendations are largely in line with current practice. Healthcare professionals may have to change some of the risk factors they look for, but there should be no resource impact for services.

Management

Specialist review and prophylactic antibiotics are part of routine current practice for babies, children and young people with recurrent bacterial meningitis and meningococcal disease. Current practice varies for adults, but bacterial meningitis and meningococcal disease are very rare and the impact on services is likely to be small (both in terms of resources and antimicrobial resistance).

[Return to recommendations](#)

Context

This guideline is for healthcare professionals (including paramedics) working in:

- primary and secondary care
- pre-hospital settings
- community settings.

Bacterial meningitis is an inflammation of the membranes that surround the brain and the spinal cord, caused by bacterial infection. We use the term 'meningococcal disease' to mean illness caused by an invasive meningococcal infection (including bloodstream infection and meningitis).

The main bacteria that cause meningitis in adults, children and babies over 3 months old are *Neisseria meningitidis* (meningococcus) and *Streptococcus pneumoniae* (pneumococcus). These 2 bacteria normally spread by person-to-person droplet transmission (for example, sneezing). *Haemophilus influenzae* type b used to be another common cause, but since vaccination started it is now rare. In babies under 3 months old, group B *Streptococcus*, *Escherichia coli* and other coliforms are common. *Listeria monocytogenes* is very rare, but occasionally causes meningitis in older people, very young children, and in people with other risk factors.

There are variations in clinical practice for bacterial meningitis and meningococcal disease, including in access to intensive care support for critically ill children and adults. There is also variation in follow-up and management for complications. This guideline aims to address these variations and promote effective, evidence-based care for people with bacterial meningitis and meningococcal disease.

Finding more information and committee details

To find NICE guidance on related topics, including guidance in development, see the [NICE topic page on meningitis and meningococcal septicaemia](#).

For full details of the evidence and the guideline committee's discussions, see the [evidence reviews](#). You can also find information about [how the guideline was developed](#), including [details of the committee](#).

NICE has produced tools and resources to help you put this guideline into practice. For general help and advice on putting our guidelines into practice, see [resources to help you put NICE guidance into practice](#).

Update information

March 2024: This guideline is an update of NICE guideline CG102 (published June 2010) and replaces it.

ISBN: 978-1-4731-5749-1

Accreditation

